Unicorn Biotechnologies develops bio-reactors that standardize, digitize, and automate cell culture workflows, enabling efficient scaling from pilot to commercial manufacturing. Their technology addresses the challenges of batch failures and high costs in cell-based production, allowing researchers to focus on experimental design and analysis.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACFounders
Product
Problem
Cell-based production faces challenges in standardization, high costs, and scalability, leading to batch failures and hindering efficient transition from pilot to commercial manufacturing. Researchers often spend more time on manual processes than on experimental design and analysis.
Solution
Unicorn Biotechnologies offers bioreactors that standardize, digitize, and automate cell culture workflows, enabling researchers to focus on experimental design and analysis. Their systems facilitate robust process development that seamlessly transfers to linearly scalable systems. This approach reduces batch failures, time, and costs associated with scaling from pilot to commercial manufacturing.
Target Audience
The primary target audience includes researchers and manufacturers in cell-based industries seeking to streamline and scale their cell culture processes.
Features
- Automated cell culture workflows to minimize manual intervention.
- Digitized process monitoring for real-time data acquisition and analysis.
- Standardized protocols to ensure consistency and reproducibility.
- Linearly scalable bioreactor systems for seamless transition from pilot to commercial manufacturing.